Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
29 April 1986Website:
http://www.repligen.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 15 min agoDividend
Analysts recommendations
Institutional Ownership
RGEN Latest News
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Evan Stock - Wells Fargo Matthew Hewitt - Craig-Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Matt Stanton - Jefferies LLC Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Third Quarter of 2024 Earnings Conference Call.
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty.
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences.
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing.
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters.
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET.
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
What type of business is Repligen?
Repligen Corporation is a global biotechnology company that develops and commercializes highly innovative biotechnological technologies and systems to enhance the efficiency and flexibility of the production process of biological products. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. The company's business is represented by a product line: Chromatography; Filtration; Process Analytics; Protein products; Other. Customers use the company's products for the production of drugs for clinical trials, then scale up to larger volumes as the drug transitions to commercial production after regulatory approval. Repligen Corporation's customers include biopharmaceutical companies, contract development organizations, and manufacturing organizations.
What sector is Repligen in?
Repligen is in the Healthcare sector
What industry is Repligen in?
Repligen is in the Medical Instruments & Supplies industry
What country is Repligen from?
Repligen is headquartered in United States
When did Repligen go public?
Repligen initial public offering (IPO) was on 29 April 1986
What is Repligen website?
https://www.repligen.com
Is Repligen in the S&P 500?
No, Repligen is not included in the S&P 500 index
Is Repligen in the NASDAQ 100?
No, Repligen is not included in the NASDAQ 100 index
Is Repligen in the Dow Jones?
No, Repligen is not included in the Dow Jones index
When was Repligen the previous earnings report?
No data
When does Repligen earnings report?
The next expected earnings date for Repligen is 21 February 2025